---
title: "Guoyuan Securities (HK) Reaffirms Their Buy Rating on CStone Pharmaceuticals (2616)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/277565010.md"
description: "Guoyuan Securities (HK) analyst maintained a Buy rating on CStone Pharmaceuticals yesterday and set a price target of HK$10.30.Claim 50% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential CStone Pharmaceuticals has an analyst consensus of Hold."
datetime: "2026-03-03T05:06:48.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/277565010.md)
  - [en](https://longbridge.com/en/news/277565010.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/277565010.md)
---

# Guoyuan Securities (HK) Reaffirms Their Buy Rating on CStone Pharmaceuticals (2616)

Guoyuan Securities (HK) analyst maintained a Buy rating on CStone Pharmaceuticals yesterday and set a price target of HK$10.30.

### Claim 50% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

CStone Pharmaceuticals has an analyst consensus of Hold.

### Related Stocks

- [159615.CN](https://longbridge.com/en/quote/159615.CN.md)
- [159859.CN](https://longbridge.com/en/quote/159859.CN.md)
- [159849.CN](https://longbridge.com/en/quote/159849.CN.md)
- [513060.CN](https://longbridge.com/en/quote/513060.CN.md)
- [159506.CN](https://longbridge.com/en/quote/159506.CN.md)
- [159837.CN](https://longbridge.com/en/quote/159837.CN.md)
- [516930.CN](https://longbridge.com/en/quote/516930.CN.md)
- [588860.CN](https://longbridge.com/en/quote/588860.CN.md)
- [520880.CN](https://longbridge.com/en/quote/520880.CN.md)
- [516820.CN](https://longbridge.com/en/quote/516820.CN.md)
- [159102.CN](https://longbridge.com/en/quote/159102.CN.md)
- [512290.CN](https://longbridge.com/en/quote/512290.CN.md)
- [588130.CN](https://longbridge.com/en/quote/588130.CN.md)
- [159316.CN](https://longbridge.com/en/quote/159316.CN.md)
- [513700.CN](https://longbridge.com/en/quote/513700.CN.md)
- [159992.CN](https://longbridge.com/en/quote/159992.CN.md)
- [560600.CN](https://longbridge.com/en/quote/560600.CN.md)
- [513120.CN](https://longbridge.com/en/quote/513120.CN.md)
- [520690.CN](https://longbridge.com/en/quote/520690.CN.md)
- [02616.HK](https://longbridge.com/en/quote/02616.HK.md)
- [159892.CN](https://longbridge.com/en/quote/159892.CN.md)
- [516500.CN](https://longbridge.com/en/quote/516500.CN.md)
- [588250.CN](https://longbridge.com/en/quote/588250.CN.md)

## Related News & Research

- [Xuanzhu Biopharm Wins Green Light for Phase III Anaprazole Trial in H. pylori](https://longbridge.com/en/news/282752451.md)
- [RaySearch wins first RayCare order in China from P-Cure for Shanghai center](https://longbridge.com/en/news/283100924.md)
- [CICC Reaffirms Their Buy Rating on Livzon Pharmaceutical Group (LVZPF)](https://longbridge.com/en/news/282769048.md)
- [AbbVie bets on Chinese biopharma’s pain pipeline in $745m bid](https://longbridge.com/en/news/282533515.md)
- [Cutia Therapeutics’ Botox Rival Meets Phase III Goals in China](https://longbridge.com/en/news/282464943.md)